Ziltivekimab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Acute Myocardial InfarctionAtherosclerosisHeart Attack

75 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

1

Plavix

Sanofi

Approved

62

Bayer Aspirin

Bayer

Approved

23

Radicava

Shionogi

Approved

14

Praluent

Regeneron

Approved

15

Zebeta

Teva

Approved

16

Neoral

Novartis

Approved

—7

Leqvio

Novartis

Approved

—8

Onglyza

AstraZeneca

Approved

—9

Angiomax

BBaxter Healthcare Corporation

Approved

310

Effient

CCosette Pharmaceuticals, Inc.

Approved

2Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Chronic Renal Disease2 trials

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Completed·Novo Nordisk·Phase 2·NCT03926117·264 enrolled

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.

Completed·Novo Nordisk·Phase 2·NCT04626505·36 enrolled

Heart Failure2 trials

Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Terminated·Novo Nordisk·Phase 3·NCT05636176·4,899 enrolled

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Active, not recruiting·Novo Nordisk·Phase 3·NCT06200207·680 enrolled

Cardiovascular Risk2 trials

ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

Active, not recruiting·Novo Nordisk·Phase 3·NCT06118281·10,000 enrolled

ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation

Completed·Novo Nordisk·Phase 3·NCT05021835·6,385 enrolled

Acute Myocardial Infarction1 trial

Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

Recruiting·EECRI bv·Phase 3·NCT07276282·332 enrolled

Kidney Disease1 trial

A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation

Completed·Novo Nordisk·Phase 1·NCT05379829·24 enrolled

3 more indications

Heart Attack1 trial

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

Recruiting·Novo Nordisk·Phase 3·NCT07301034·332 enrolled

Atherosclerosis1 trial

Specifying the Anti-inflammatory Effects of Ziltivekimab With Diverse Imaging Modalities and In-depth Cellular Phenotyping

Active, not recruiting·AAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·Phase 3·NCT06263244·40 enrolled

Unspecified1 trial

A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab

Completed·Novo Nordisk·Phase 1·NCT05721989·267 enrolled

Details

Drug Info

Related News